SCOUT-HCM: Mavacamten Outperforms Placebo in Adolescents With HCM, With Joseph Rossano, MD, MS

16 Visioni

  • Grazie! Condividilo con i tuoi amici!

    Non hai gradito questo video. Grazie per il feedback!

admin
Published
Mavacamten exhibited greater reduction of left ventricular outflow compared to placebo in adolescent patients with obstructive hypertrophic cardiomyopathy (oHCM), according to data from the SCOUT-HCM trial.
These data were presented at the American College of Cardiology (ACC) Scientific Sessions 2026 in New Orleans, Louisiana, by Joseph Rossano, MD, MS, co-director of the Cardiac Center and chief of the division of cardiology at the Children’s Hospital of Philadelphia, as well as the Jennifer Terker Endowed Chair in Pediatric Cardiology.
In an interview with HCPLive, Rossano discusses the results of the phase 3 SCOUT-HCM trial, highlighting mavacamten's comparative superiority to placebo in reducing left ventricular outflow in adolescents with HCM.

“Prior to this, what we used for children was really aimed at helping to alleviate their symptoms, and it wasn’t actually based on very strong evidence that it was helpful for those patients,” Rossano said. “It’s really extrapolated from what we use for adult patients. To see such dramatic reductions in the gradients, as well as the improvements in the secondary endpoints, is really encouraging.”

Read the full article here: https://www.hcplive.com/view/scout-hcm-mavacamten-outperforms-placebo-in-adolescents-with-hcm-with-joseph-rossano-md-ms

Key Timestamps
00:00:01 Intro
00:00:08 Study Overview
00:01:45 Interpreting the LVOT gradient reductions
00:02:37 Remodeling or secondary effects?
00:03:19 Endpoints vs. patient-reported outcomes
00:04:11 NT-proBNP and troponin
00:04:50 Patient subgroups with different risks

#cardiology #acc26 #hcm
Categoria
Cardiology
Commenta per primo questo video.

Prossimo